Skip to main content
HairCited

الحديد لـ تساقط الشعر الكربي (Telogen Effluvium)

B الأدلة تدعم ذلك تجربة عشوائية واحدة على الأقل، مع نتائج متسقة في معظمها.

بناءً على 56 دراسة (2 RCTs) بمشاركة 11,067 مشاركًا إجمالاً. النتائج متباينة بين الدراسات.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Diron\u0026condition\u003Dtelogen\u002Deffluvium'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

الخلاصة

Iron may support recovery from telogen effluvium, particularly when low ferritin levels are confirmed, but the evidence is mixed and routine supplementation without testing is not well-supported.

  • 56 studies provide substantial evidence, though results are mixed across the research
  • Lower ferritin levels are commonly found in patients with telogen effluvium
  • One study found iron supplementation improved satisfaction even in patients without overtly low ferritin
  • Blood testing for ferritin and iron levels is recommended before starting supplementation

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None مقابل: None Outcome: None التأثير: None None

المجتمع المدروس: women with androgenetic alopecia (female pattern hair loss)

scoping_review n=16
A Scoping Review of Exosome Delivery Applications in Hair Loss.
Dose: variable; exosomes predominantly from mesenchymal stem cells (MSCs) مقابل: Placebo التأثير: None None
Review
Research progress in the treatment of non-scarring alopecia: mechanism and treatment.
Dose: None مقابل: Placebo التأثير: None None
Retrospective cohort n=2851
Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience.
Dose: None مقابل: Placebo التأثير: Ferritin low in 46.5% of patients; iron deficiency in 29.5% p<0.05
review
The role of microtrauma in hair regrowth and regeneration in non-scarring alopecia.
Dose: Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera مقابل: Placebo التأثير: Positive outcomes reported for hair density and thickness with microneedling, lasers, LLLT, and PRP None

Key Statistics

62

الدراسات

11072

المشاركون

Mixed

B

التقييم

Referenced Papers

Biomedicines 2024 17 اقتباسات
Journal of drugs … 2021 3 اقتباسات
International journal of … 2016 28 اقتباسات
Acta dermatovenerologica Croatica … 2016 6 اقتباسات
Journal of clinical … 2015 190 اقتباسات
The Medical clinics … 2015 66 اقتباسات
Journal of clinical … 2015 41 اقتباسات
Clinical obstetrics and … 2015 9 اقتباسات
Turkish journal of … 2014 5 اقتباسات
Annals of gastroenterology 2014 5 اقتباسات
Skin pharmacology and … 2013 127 اقتباسات
Indian journal of … 2009 109 اقتباسات
Seminars in cutaneous … 2006 23 اقتباسات
American journal of … 2005 140 اقتباسات
Journal of the … 2005 64 اقتباسات
Revue medicale de … 2004
The Journal of … 2003 222 اقتباسات
International journal of … 2002 95 اقتباسات
Dermatologic clinics 1993 38 اقتباسات

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

الجرعات الشائعة

general:
18 mg/day (women)
deficiency:
65-200 mg elemental iron/day

الحد الأعلى: 45 mg/day

الجرعات المدروسة في الأبحاث

الجرعة المدة التأثير ن
None -- Neutral --
variable; exosomes predominantly from mesenchymal stem cells (MSCs) -- Positive 16
None -- Mixed --
None -- Neutral 2851
Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera -- Positive --
None -- Positive --
not applicable (observational; serum ferritin measured) -- Negative 100
None -- Mixed --

أفضل وقت للتناول: On an empty stomach with vitamin C for best absorption; take 2 hours apart from calcium

Safety & Side Effects

الآثار الجانبية المُبلّغ عنها

  • Constipation (most common)
  • Nausea and stomach cramps
  • Dark or black stools
  • Iron overload with excessive supplementation (hemochromatosis risk)

التفاعلات المعروفة

  • Calcium supplements and dairy (reduce iron absorption by 50-60%)
  • Proton pump inhibitors (omeprazole) and H2 blockers reduce absorption
  • Tetracycline and quinolone antibiotics (mutual absorption reduction)
  • Levothyroxine (iron reduces thyroid hormone absorption)

الحد الأقصى المسموح به: 45 mg/day

استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.

Frequently Asked Questions

Does الحديد help with تساقط الشعر الكربي (Telogen Effluvium)?
Based on 62 studies with 11,072 participants, there is moderate evidence from clinical studies that الحديد may support تساقط الشعر الكربي (Telogen Effluvium) management. Our evidence grade is B (Good Evidence).
How much الحديد should I take for تساقط الشعر الكربي (Telogen Effluvium)?
Studies have used various dosages. A commonly studied range is 18 mg/day (women). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of الحديد?
Reported side effects may include Constipation (most common), Nausea and stomach cramps, Dark or black stools, Iron overload with excessive supplementation (hemochromatosis risk). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for الحديد and تساقط الشعر الكربي (Telogen Effluvium)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 62 peer-reviewed studies with 11,072 total participants. The overall direction of effect is mixed.

References

  1. [1] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
  2. [2] Fatemeh Chinisaz et al.. Obes Surg. 2026. Comparative Analysis of Postoperative Hair Loss and Micronutrient Deficiencies After One-Anastomosis Gastric Bypass Versus Sleeve Gastrectomy. doi:10.1007/s11695-026-08597-2 PubMed
  3. [3] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
  4. [4] Ömer Karakoyun et al.. J Cosmet Dermatol. 2025. Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience. doi:10.1111/jocd.70037 PubMed
  5. [5] Andrea Sechi et al.. Nutrients. 2025. Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients. doi:10.3390/nu17091451 PubMed
  6. [6] Luis A Mendoza et al.. Cureus. 2025. Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation. doi:10.7759/cureus.82991 PubMed
  7. [7] Xuexue Pan et al.. Aesthetic Plast Surg. 2025. Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. doi:10.1007/s00266-025-05077-3 PubMed
  8. [8] Rui-Xian Guo et al.. Front Pharmacol. 2025. Research progress in the treatment of non-scarring alopecia: mechanism and treatment. doi:10.3389/fphar.2025.1544068 PubMed
  9. [9] Woo C Tay et al.. Ital J Dermatol Venerol. 2025. The role of microtrauma in hair regrowth and regeneration in non-scarring alopecia. doi:10.23736/S2784-8671.25.08232-5 PubMed
  10. [10] Adam Leavitt et al.. J Drugs Dermatol. 2025. Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. doi:10.36849/JDD.8763 PubMed
  11. [11] Namrata Chhabra et al.. Int J Trichology. 2025. Telogen Effluvium Following Coronavirus Disease-2019 Infection: A Retrospective Study of 113 Cases. doi:10.4103/ijt.ijt_38_22 PubMed
  12. [12] Nishantan Thamotharan et al.. Cureus. 2025. Assessment of Serum Ferritin Levels in Female Patients With Telogen Effluvium. doi:10.7759/cureus.100249 PubMed
  13. [13] Barbara Owecka et al.. Biomedicines. 2024. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. doi:10.3390/biomedicines12030513 PubMed
  14. [14] Irem Nur Durusu Turkoglu et al.. J Cosmet Dermatol. 2024. A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, vitamin B12, vitamin D, thyroid … doi:10.1111/jocd.16512 PubMed
  15. [15] Shuxuan Li et al.. Int J Pharm. 2024. Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. doi:10.1016/j.ijpharm.2024.124585 PubMed
  16. [16] Nermeen Ibrahim Bedair et al.. Arch Dermatol Res. 2024. Post Covid telogen effluvium: the diagnostic value of serum ferritin biomarker and the preventive value of dietary supplements. a case … doi:10.1007/s00403-024-03004-1 PubMed
  17. [17] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
  18. [18] Xuefei Zhang et al.. Int J Nanomedicine. 2024. Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. doi:10.2147/IJN.S477820 PubMed
  19. [19] Rhiannon C Miller et al.. Arch Dermatol Res. 2024. Cost-effectiveness analysis of laboratory monitoring in newly diagnosed telogen effluvium patients. doi:10.1007/s00403-024-02948-8 PubMed
  20. [20] Leyla Bilik et al.. North Clin Istanb. 2024. Evaluation of the relationship of digital phototrichogram findings of patients with diffuse hair loss with blood TSH, ferritin and vitamin … doi:10.14744/nci.2023.33269 PubMed
  21. [21] Massimo Milani et al.. Skin Res Technol. 2023. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair … doi:10.1111/srt.13381 PubMed
  22. [22] Vivien Chen et al.. Pediatr Dermatol. 2023. Etiology, management, and outcomes of pediatric telogen effluvium: A single-center study in the United States. doi:10.1111/pde.15154 PubMed
  23. [23] Rhiannon C Miller et al.. J Am Acad Dermatol. 2023. "Shedding" low yield testing for telogen effluvium: A cross-sectional study of 16,381 laboratory results from newly diagnosed patients. doi:10.1016/j.jaad.2023.05.045 PubMed
  24. [24] Hakan Arslan et al.. Dermatol Pract Concept. 2023. Micronutrient Deficiencies and Digital Computerized Phototrichogram Analysis in Telogen Effluvium: a Retrospective Correlation Study in a Tertiary Medical Center. doi:10.5826/dpc.1303a202 PubMed
  25. [25] Michela Starace et al.. Ital J Dermatol Venerol. 2023. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … doi:10.23736/S2784-8671.22.07416-3 PubMed
  26. [26] Ahu Yorulmaz et al.. J Cosmet Dermatol. 2022. Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium. doi:10.1111/jocd.14413 PubMed
  27. [27] Ümran Öner et al.. Turk J Med Sci. 2022. Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom? doi:10.3906/sag-2106-28 PubMed
  28. [28] Saadet İbiş et al.. Dermatol Pract Concept. 2022. Evaluation of MCV/RDW Ratio and Correlations With Ferritin in Telogen Effluvium Patients. doi:10.5826/dpc.1203a151 PubMed
  29. [29] Elizabeth J Klein et al.. JAAD Int. 2022. Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. doi:10.1016/j.jdin.2022.08.013 PubMed
  30. [30] Muhammad Fawad Aslam et al.. Cureus. 2022. The Association of Serum Ferritin Levels With Non-scarring Alopecia in Women. doi:10.7759/cureus.32123 PubMed
  31. [31] Efe Kakpovbia et al.. J Drugs Dermatol. 2021. Laboratory Testing in Telogen Effluvium. doi:10.36849/JDD.5771 PubMed
  32. [32] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
  33. [33] Rodney D Sinclair. Int J Dermatol. 2018. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. doi:10.1111/ijd.13838 PubMed
  34. [34] Flávia Alvim Sant'Anna Addor et al.. Clin Cosmet Investig Dermatol. 2018. Comparative evaluation between two nutritional supplements in the improvement of telogen effluvium. doi:10.2147/CCID.S173082 PubMed
  35. [35] Ibrahim Halil Yavuz et al.. Indian J Dermatol. 2018. Assessment of Heavy Metal and Trace Element Levels in Patients with Telogen Effluvium. doi:10.4103/ijd.IJD_610_17 PubMed
  36. [36] Dinesh Gowda et al.. Int J Trichology. 2017. Prevalence of Nutritional Deficiencies in Hair Loss among Indian Participants: Results of a Cross-sectional Study. doi:10.4103/ijt.ijt_48_16 PubMed
  37. [37] Evelyn J Cheung et al.. J Drugs Dermatol. 2016. Vitamin and Mineral Deficiencies in Patients With Telogen Effluvium: A Retrospective Cross-Sectional Study. PubMed
  38. [38] Tee Wei Siah et al.. Int J Trichology. 2016. Female Pattern Hair Loss: A Retrospective Study in a Tertiary Referral Center. doi:10.4103/0974-7753.188033 PubMed
  39. [39] Kirti Deo et al.. Dermatol Res Pract. 2016. Clinicoepidemiological Observational Study of Acquired Alopecias in Females Correlating with Anemia and Thyroid Function. doi:10.1155/2016/6279108 PubMed
  40. [40] Caroline Bittencourt et al.. Int J Dermatol. 2016. Non-invasive method distinguishes chronic telogen effluvium from mild female pattern hair loss: clinicopathological correlation. doi:10.1111/ijd.13200 PubMed
  41. [41] Jana Zímová et al.. Acta Dermatovenerol Croat. 2016. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. PubMed
  42. [42] Shashikant Malkud. J Clin Diagn Res. 2015. Telogen Effluvium: A Review. doi:10.7860/JCDR/2015/15219.6492 PubMed
  43. [43] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
  44. [44] Shashikant Malkud. J Clin Diagn Res. 2015. A Hospital-based Study to Determine Causes of Diffuse Hair Loss in Women. doi:10.7860/JCDR/2015/14089.6170 PubMed
  45. [45] Abeer M Abdel Aziz et al.. Int J Trichology. 2015. Possible Relationship between Chronic Telogen Effluvium and Changes in Lead, Cadmium, Zinc, and Iron Total Blood Levels in Females: A … doi:10.4103/0974-7753.167465 PubMed
  46. [46] Katya L Harfmann et al.. Clin Obstet Gynecol. 2015. Hair loss in women. doi:10.1097/GRF.0000000000000081 PubMed
  47. [47] Nicolas Perez-Mora et al.. Dermatol Ther. 2014. Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. doi:10.1111/dth.12101 PubMed
  48. [48] Thamer Mubki. J Cutan Med Surg. 2014. Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia. doi:10.2310/7750.2014.14008 PubMed
  49. [49] Hatice Uce Özkol et al.. Turk J Med Sci. 2014. Is TrichoScan a new diagnostic method for diffuse hair loss? doi:10.3906/sag-1212-78 PubMed
  50. [50] Maria Rogalidou et al.. Ann Gastroenterol. 2014. Telogen effluvium as the first symptom of Crohn's disease in a child. PubMed
  51. [51] H Rasheed et al.. Skin Pharmacol Physiol. 2013. Serum ferritin and vitamin d in female hair loss: do they play a role? doi:10.1159/000346698 PubMed
  52. [52] Khitam Al-Refu. Int J Trichology. 2013. Hair loss in children: common and uncommon causes; clinical and epidemiological study in jordan. doi:10.4103/0974-7753.130393 PubMed
  53. [53] Elise A Olsen et al.. J Am Acad Dermatol. 2010. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. doi:10.1016/j.jaad.2009.12.006 PubMed
  54. [54] Shyam Behari Shrivastava. Indian J Dermatol Venereol Leprol. 2009. Diffuse hair loss in an adult female: approach to diagnosis and management. doi:10.4103/0378-6323.45215 PubMed
  55. [55] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
  56. [56] Leonid Benjamin Trost et al.. J Am Acad Dermatol. 2006. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. doi:10.1016/j.jaad.2005.11.1104 PubMed
  57. [57] Maria K Hordinsky. Semin Cutan Med Surg. 2006. Medical treatment of noncicatricial alopecia. doi:10.1016/j.sder.2006.01.007 PubMed
  58. [58] Renata Strumia. Am J Clin Dermatol. 2005. Dermatologic signs in patients with eating disorders. doi:10.2165/00128071-200506030-00003 PubMed
  59. [59] Rodney Sinclair. J Am Acad Dermatol. 2005. Chronic telogen effluvium: a study of 5 patients over 7 years. doi:10.1016/j.jaad.2004.05.040 PubMed
  60. [60] V del Marmol et al.. Rev Med Brux. 2004. [Androgenetic alopecia]. PubMed
  61. [61] Jonathan Kantor et al.. J Invest Dermatol. 2003. Decreased serum ferritin is associated with alopecia in women. doi:10.1046/j.1523-1747.2003.12540.x PubMed
  62. [62] D H Rushton et al.. Int J Cosmet Sci. 2002. Causes of hair loss and the developments in hair rejuvenation. doi:10.1046/j.0412-5463.2001.00110.x PubMed
  63. [63] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed

إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.